Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8707 |
High Similarity |
NPD37 |
Approved |
0.8626 |
High Similarity |
NPD3705 |
Approved |
0.8533 |
High Similarity |
NPD4967 |
Phase 2 |
0.8533 |
High Similarity |
NPD4965 |
Approved |
0.8533 |
High Similarity |
NPD4966 |
Approved |
0.8421 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8194 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8138 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8129 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8089 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8077 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.805 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7986 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7905 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7883 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7853 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7832 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7832 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7826 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7826 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7817 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7801 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7801 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.773 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7655 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7622 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7586 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7586 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7566 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7562 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7554 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.755 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7546 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7535 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7464 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7455 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.745 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7447 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7438 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7417 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.74 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7394 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7386 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7383 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7372 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7361 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7338 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7329 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7329 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7329 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7325 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7324 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7324 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7296 |
Intermediate Similarity |
NPD3382 |
Approved |
0.7296 |
Intermediate Similarity |
NPD3384 |
Approved |
0.7296 |
Intermediate Similarity |
NPD3383 |
Approved |
0.7286 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7286 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7278 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7266 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7256 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7255 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7251 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7215 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7205 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7202 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.72 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7194 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7191 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7183 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7181 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7172 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7171 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7171 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7171 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7163 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7161 |
Intermediate Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7127 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7118 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7117 |
Intermediate Similarity |
NPD4055 |
Discovery |
0.7114 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7114 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7107 |
Intermediate Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7101 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7095 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7092 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7066 |
Intermediate Similarity |
NPD4481 |
Phase 3 |
0.7063 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7063 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7059 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7055 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7055 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.705 |
Intermediate Similarity |
NPD709 |
Approved |
0.705 |
Intermediate Similarity |
NPD6387 |
Discontinued |
0.7048 |
Intermediate Similarity |
NPD3051 |
Approved |
0.7048 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7041 |
Intermediate Similarity |
NPD8156 |
Discontinued |
0.7039 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7037 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7037 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7034 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7025 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD1139 |
Approved |
0.7007 |
Intermediate Similarity |
NPD228 |
Approved |
0.7007 |
Intermediate Similarity |
NPD1137 |
Approved |
0.6994 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6986 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6985 |
Remote Similarity |
NPD5451 |
Approved |
0.6982 |
Remote Similarity |
NPD8099 |
Discontinued |
0.6982 |
Remote Similarity |
NPD8252 |
Approved |
0.6982 |
Remote Similarity |
NPD8251 |
Approved |
0.698 |
Remote Similarity |
NPD6812 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD7808 |
Phase 3 |
0.6977 |
Remote Similarity |
NPD7549 |
Discontinued |
0.697 |
Remote Similarity |
NPD919 |
Approved |
0.6968 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6964 |
Remote Similarity |
NPD6166 |
Phase 2 |
0.6964 |
Remote Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.6962 |
Remote Similarity |
NPD2534 |
Approved |
0.6962 |
Remote Similarity |
NPD2532 |
Approved |
0.6962 |
Remote Similarity |
NPD2533 |
Approved |
0.6959 |
Remote Similarity |
NPD6797 |
Phase 2 |
0.6957 |
Remote Similarity |
NPD5535 |
Approved |
0.6957 |
Remote Similarity |
NPD1138 |
Approved |
0.6951 |
Remote Similarity |
NPD6788 |
Approved |
0.6933 |
Remote Similarity |
NPD2977 |
Approved |
0.6933 |
Remote Similarity |
NPD2978 |
Approved |
0.6933 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD8032 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6919 |
Remote Similarity |
NPD7251 |
Discontinued |
0.6918 |
Remote Similarity |
NPD2922 |
Phase 1 |
0.6918 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD6696 |
Suspended |
0.6918 |
Remote Similarity |
NPD1283 |
Approved |
0.6914 |
Remote Similarity |
NPD5090 |
Approved |
0.6914 |
Remote Similarity |
NPD5089 |
Approved |
0.6909 |
Remote Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD6353 |
Approved |
0.6908 |
Remote Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD2970 |
Approved |
0.6905 |
Remote Similarity |
NPD2969 |
Approved |
0.6905 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6903 |
Remote Similarity |
NPD4664 |
Clinical (unspecified phase) |
0.6899 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6894 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6887 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6886 |
Remote Similarity |
NPD1247 |
Approved |
0.6885 |
Remote Similarity |
NPD5006 |
Approved |
0.6885 |
Remote Similarity |
NPD5005 |
Approved |
0.6883 |
Remote Similarity |
NPD2796 |
Approved |
0.6883 |
Remote Similarity |
NPD6100 |
Approved |
0.6883 |
Remote Similarity |
NPD6099 |
Approved |
0.6879 |
Remote Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD4727 |
Phase 1 |
0.6863 |
Remote Similarity |
NPD6896 |
Approved |
0.6863 |
Remote Similarity |
NPD6895 |
Approved |
0.6863 |
Remote Similarity |
NPD7119 |
Phase 2 |
0.6863 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6861 |
Remote Similarity |
NPD3021 |
Approved |
0.6861 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.6861 |
Remote Similarity |
NPD3022 |
Approved |
0.6859 |
Remote Similarity |
NPD4237 |
Approved |
0.6859 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6855 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD4584 |
Approved |
0.6855 |
Remote Similarity |
NPD7446 |
Clinical (unspecified phase) |
0.6852 |
Remote Similarity |
NPD4675 |
Approved |
0.6852 |
Remote Similarity |
NPD4678 |
Approved |
0.6849 |
Remote Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.6846 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6842 |
Remote Similarity |
NPD1933 |
Approved |
0.6842 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6839 |
Remote Similarity |
NPD4577 |
Approved |
0.6839 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6839 |
Remote Similarity |
NPD4578 |
Approved |
0.6836 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6829
|
Remote Similarity |
NPD4585 |
Approved |